Skip to main content

Table 1 Main characteristics of the eligible studies

From: Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies

Study

Patients’ country

No. of patients

Tumor stagea

Treatment methods

Cutoff value

Specimen type

Breast cancer

 Johansen 1995 [9]

Denmark

41

–

Chemotherapy

207 μg/L

Serum

 Jensen 2003 [21]

Denmark

100

Metastatic disease (100)

Chemotherapy

168 μg/L

Serum

 Johansen 2003 [22]

England

271

–

Surgery and chemotherapy and radiotherapy

–

Serum

 Yamac 2008 [29]

Turkey

45

I–III (62.2)

Surgery and chemotherapy

–

Serum

 Wang 2012 [38]

China

120

TNM I–III (23.3)

Surgery

–

Serum

Gastrointestinal tumors

 Cintin 1999 [18]

Denmark

603

Dukes’ staging A–D (53.4)

Surgery

247 μg/L

Serum

 Chang 2009 [30]

America

52

II–III (–)

Chemotherapy and radiotherapy

Continuous variable

Plasma

 Zhu 2012 [39]

China

212

–

Chemoembolization

106 μg/L

Serum

 Zhu 2012 [40]

China

158

TNM I–IV (38.0)

Surgery

Continuous variable

Serum

 Schultz 2013 [41]

Denmark and Germany

103

–

Surgery; chemotherapy (not undergoing surgery)

116 μg/L

Plasma

370

 Liu 2014 [43]

China

86

UICC I–IV (44.2)

Surgery and chemotherapy

216 μg/L

Serum

 Tarpgaard 2014 [44]

32 Nordic centers

510

Metastatic disease (100)

Chemotherapy

Continuous variable

Plasma

 Jensen 2016 [47]

Denmark

162

Metastatic disease (100)

Cetuximab and irinotecan

Continuous variable

Plasma

98

 Thongsom 2016 [50]

Thailand

57

TNM I–IV (78.9)

Surgery

100.7 μg/L

Plasma

 Gramkow 2017 [52]

Finland

457

Metastatic disease (100)

Liver resection

–

Serum

 Fuksiewicz 2018 [55]

Poland

83

–

Surgery

44.6 μg/L

Serum

Ovarian cancer

 Dehn 2003 [19]

Denmark

73

I–IV (75.3)

Chemotherapy

160 μg/L

Plasma

 Høgdall 2003 [20]

Denmark

47

III(100)

Surgery

130 μg/L

Plasma

 Høgdall 2009 [31]

Denmark

76

I–IV (72.4)

Surgery and chemotherapy

–

Plasma

 Boisen 2016 [49]

Denmark

140

FIGO I–IV (82.1)

Bevacizumab

–

Plasma

Lung cancer

 Johansen 2004 [23]

Denmark

131

Limited and extended disease (55.0)

Chemotherapy

–

Serum

 Choi 2010 [34]

Korea

39

IIIB–IV (100)

Chemotherapy

165 μg/L

Serum

 Thöm 2010 [35]

Germany

189

III–IV (100)

Chemotherapy

209 μg/L

Serum

 Xu 2014 [46]

China

120

Limited and extended disease (41.7)

Chemotherapy

65.7 μg/L

Serum

 Matsuo 2019 [57]

Japan

50

III–IV (100)

Anti-PD-1 inhibitor

–

Plasma

Urologic neoplasms

 Brasso 2006 [24]

Denmark

152

Metastatic disease (100)

Endocrine therapy

104 μg/L

Serum

 Johansen 2007 [27]

Denmark

102

–

Total androgen ablation or parenteral estrogen

Continuous variable

Serum

 Tschirdewahn 2014 [45]

Germany

101

T stage Ta–T4 (45.5)

Surgery

90 μg/L

Serum

 Vom Dorp 2016 [48]

Germany

152

Stage pT1–T4 (40.1)

Surgery

185 μg/L

Serum

 Väänänen 2017 [54]

Finland

82

Metastatic and non-metastatic disease (25.6)

Surgery

120 μg/L

Serum

 Darr 2018 [56]

Germany

109

Metastatic disease(100)

Chemotherapy

160 μg/L

Serum

Melanoma

 Schmidt 2006 [25]

Denmark

225

I–II (0)

Surgery

124 μg/L

Serum

 Schmidt 2006 [26]

Denmark

110

IV (100)

Chemotherapy and immunotherapy

124 μg/L

Serum

 Krogh 2016 [51]

Europe

299

Stage IIB and III (–)

Untreated

Continuous variable

Serum

 Erturk 2017 [53]

Turkey

112

–

chemotherapy and radiotherapy and immunotherapy

174.88 μgL

Serum

Squamous cell carcinoma of the head and neck

 Roslind 2008 [28]

Denmark

144

I–IV (55.6)

Radiotherapy

–

Serum

Multiple tumors

 Johansen 2009 [32]

Denmark

1432

Localized disease and metastatic disease (40.8)

–

–

Plasma

Cervical adenocarcinoma

 Mitsuhashi 2009 [33]

Japan

37

I–IV (29.7)

Surgery and chemoradiation

130 μg/L

Serum

Glioblastoma

 Iwamoto 2011 [36]

America

141

–

Surgery

98 μg/L

Serum

 Bernardi 2012 [37]

Italy

60

Astrocytoma

Grade IV (100)

Surgery and irradiation and chemotherapy

–

Serum

 Gállego 2014 [42]

France

111

–

Surgery

60 μg/L

Plasma

  1. – not reported
  2. aTumor stage and proportion of advanced stage(%)